Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 264 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Glucocorticoids Clear all
Completed No phase listed Observational

CGM Utilization With IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU

NCT05857007
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hyperglycemia
Interventions
Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate

NCT01199029
View directory record Official record
Conditions
Healthy
Interventions
PF-04308515, Prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2010 · Synced Oct 20, 2026, 2:01 PM EDT
Terminated Phase 2 Interventional Results available

Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)

NCT01212588
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
mifepristone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 64 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

NCT00805207
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Obstructive Sleep Apnea, Obesity
Interventions
Progesterone, testosterone, glucocorticoid, continuous positive airway pressure, Estrogen, Control
Drug · Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics

NCT02286609
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Deflazacort
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

Tocilizumab Plus a Short Prednisone Taper for GCA

NCT03726749
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Tocilizumab, Prednisone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)

NCT01027884
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne, Ambulatory Care
Interventions
Placebo, Idebenone
Drug
Lead sponsor
Santhera Pharmaceuticals
Industry
Eligibility
10 Years to 18 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 20, 2026, 2:01 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19

NCT04964414
View directory record Official record
Conditions
Dysosmia, Anosmia, Covid19
Interventions
Smell Retraining, Budesonide
Other · Drug
Lead sponsor
Amanda Stapleton
Other
Eligibility
6 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 20, 2026, 2:01 PM EDT
Recruiting Early Phase 1 Interventional

Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder

NCT06934915
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder, Autism
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Christopher John McDougle, M.D.
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 2:01 PM EDT
Terminated No phase listed Observational

CT-Based Changes in Bone and Marrow Among Patients on Oral Steroids

NCT04518722
View directory record Official record
Conditions
Asthma, Bone Density, Low, Oral Steroid-Dependent Asthma (Disorder)
Interventions
CT Scan, DXA Scan, Steroid Intake Questionnaire
Radiation · Other
Lead sponsor
University of Iowa
Other
Eligibility
25 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of 2-Week Treatment With Inhaled AZD7594 in Adolescents (12 to 17 Years) With Asthma

NCT03976869
View directory record Official record
Conditions
Asthma
Interventions
AZD7594
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Rolling Hills Estates, California • Miami, Florida • Miami Lakes, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 20, 2026, 2:01 PM EDT
Terminated Phase 3 Interventional

Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)

NCT00005777
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo
Procedure · Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
5 Minutes to 10 Days
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 20, 2026, 2:01 PM EDT
Active, not recruiting Phase 1 Interventional

Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen

NCT00706420
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Islet Transplantation + Immunosuppression, Islet cell transplantation
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 20, 2026, 2:01 PM EDT
Recruiting Phase 4 Interventional

Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting

NCT07542314
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
ELEVIDYS, Sirolimus, Glucocorticoids, Antibiotics
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 2:01 PM EDT
Terminated Phase 2 Interventional

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris

NCT00429533
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Dapsone
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
8
States / cities
Chicago, Illinois • Detroit, Michigan • Camden, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2007 · Synced Oct 20, 2026, 2:01 PM EDT
Recruiting Phase 2 Interventional

Dynamic Treatment Regiments for Glucocorticoid Tapering

NCT06072768
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
15-day taper prednisone, 150-day taper prednisone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 20, 2026, 2:01 PM EDT
Recruiting Phase 1 Interventional

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

NCT06225310
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
Selinexor, Ruxolitinib, Methylprednisolone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study

NCT04177940
View directory record Official record
Conditions
Osteoporosis
Interventions
DMAB Discontinuation and Switching
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer

NCT05190770
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV
Interventions
Triamcinolone Acetonide, Oleogel-S10
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 20, 2026, 2:01 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

NCT06246513
View directory record Official record
Conditions
Limb-girdle Muscular Dystrophy
Interventions
SRP-9003, Glucocorticoid
Biological · Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
4
States / cities
La Jolla, California • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 20, 2026, 2:01 PM EDT
Terminated Phase 2 Interventional Results available

A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

NCT04544410
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Tildacerfont/Placebo
Drug
Lead sponsor
Spruce Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

NCT04123561
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
TLC599, DSP, Normal Saline
Drug · Other
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
40 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 20, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists

NCT01548417
View directory record Official record
Conditions
Alcoholism
Interventions
Korlym (mifepristone), Sugar Pill
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 20, 2026, 2:01 PM EDT
Recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 20, 2026, 2:01 PM EDT